Scoring Systems for Immunohistochemistry in Urothelial Carcinoma

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2023 Jul 6

PMID 37410225

Authors

Mark-Sebastian Bosherz

Iryna V Samarska

Nadine T Gaisa

Affiliations

Soon will be listed here.

Abstract

Immunohistochemistry is widely used in diagnostic and scientific analysis of urothelial carcinoma. Objective interpretation of staining results is mandatory for accuracy and comparability in diagnostic and therapeutic patient care as well as research.Herein we summarize and explain standardized microscopic evaluation and scoring approaches for immunohistochemical stainings. We focus on commonly used and generally feasible approaches for different cellular compartments and comment on their utility in diagnostics and research practice.

Citing Articles

Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy.

Shalaby A, Mahmoud H, Sayed S, Al Hashmi K, Al-Sinawi S, Al Badi S Asian Pac J Cancer Prev. 2024; 25(6):2193-2201.

PMID: 38918683 PMC: 11382872. DOI: 10.31557/APJCP.2024.25.6.2193.

References

Magaki S, Hojat S, Wei B, So A, Yong W . An Introduction to the Performance of Immunohistochemistry. Methods Mol Biol. 2018; 1897:289-298. PMC: 6749998. DOI: 10.1007/978-1-4939-8935-5_25. View

Sukswai N, Khoury J . Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection. Curr Hematol Malig Rep. 2019; 14(5):368-375. DOI: 10.1007/s11899-019-00533-9. View

Amin M, Trpkov K, Lopez-Beltran A, Grignon D . Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014; 38(8):e20-34. DOI: 10.1097/PAS.0000000000000240. View

Bellizzi A . An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol. 2020; 27(3):114-163. PMC: 7700753. DOI: 10.1097/PAP.0000000000000256. View

Lopez-Beltran A, Marques R, Montironi R, Reymundo C, Fonseca J, Cheng L . Dysplasia and carcinoma in situ of the urinary bladder. Anal Quant Cytopathol Histpathol. 2015; 37(1):29-38. View

McKenney J . Urothelial carcinoma in situ: diagnostic update. Pathology. 2020; 53(1):86-95. DOI: 10.1016/j.pathol.2020.10.001. View

Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M . PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2020; 7(22):690. PMC: 6944605. DOI: 10.21037/atm.2019.10.24. View

Paver E, Cooper W, Colebatch A, Ferguson P, Hill S, Lum T . Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021; 53(2):141-156. DOI: 10.1016/j.pathol.2020.10.007. View

Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y . Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol. 2013; 64(3):465-71. DOI: 10.1016/j.eururo.2013.03.043. View

10.

Calandrella M, Francesconi S, Caprera C, Mosillo C, Caserta C, Giannarelli D . Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study. BMC Cancer. 2022; 22(1):168. PMC: 8845253. DOI: 10.1186/s12885-022-09259-z. View

11.

Rizzardi A, Johnson A, Vogel R, Pambuccian S, Henriksen J, Skubitz A . Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012; 7:42. PMC: 3379953. DOI: 10.1186/1746-1596-7-42. View

12.

Taylor C, Levenson R . Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006; 49(4):411-24. DOI: 10.1111/j.1365-2559.2006.02513.x. View

13.

Simon R, Sauter G . Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol. 2002; 30(12):1365-72. DOI: 10.1016/s0301-472x(02)00965-7. View

14.

Walker R . Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006; 49(4):406-10. DOI: 10.1111/j.1365-2559.2006.02514.x. View

15.

Meyerholz D, Beck A . Principles and approaches for reproducible scoring of tissue stains in research. Lab Invest. 2018; 98(7):844-855. DOI: 10.1038/s41374-018-0057-0. View

16.

Hamilton P, Bankhead P, Wang Y, Hutchinson R, Kieran D, McArt D . Digital pathology and image analysis in tissue biomarker research. Methods. 2014; 70(1):59-73. DOI: 10.1016/j.ymeth.2014.06.015. View

17.

Rose M, Gaisa N . Immunohistochemical Analysis of Urothelial Carcinoma Tissues for Proliferation and Differentiation Markers. Methods Mol Biol. 2017; 1655:43-52. DOI: 10.1007/978-1-4939-7234-0_4. View

18.

Kim S, Roh J, Park C . Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. J Pathol Transl Med. 2016; 50(6):411-418. PMC: 5122731. DOI: 10.4132/jptm.2016.08.08. View

19.

Helm M, Lin L . Calculating microscope field area is important for accurately determining melanoma mitotic rate. Dermatol Surg. 2011; 37(12):1820-1. DOI: 10.1111/j.1524-4725.2011.02196.x. View

20.

Bagchi S, Yuan R, Engleman E . Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2020; 16:223-249. DOI: 10.1146/annurev-pathol-042020-042741. View